Shona
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message

Submit An Free Inquiry

Our medical team will make an evaluation for you, based on the information you provided. This procedure is free of charge.

AI Helps Write
AI Helps Write

Wang Liang

Zita reChiremba: Chiremba Mukuru
Chinzvimbo: Mukuru weDhipatimendi
Nhoroondo Yake: Chiremba Mukuru, Purofesa, Mutariri wePh.D., parizvino ari Mutungamiriri weDhipatimendi reHematology rePeking Tongren Hospital. Akapedza kudzidza kuPeking Union Medical College muna 2010, achidzidza nezveClinical Medicine mumakore masere, uye akawana dhigirii reDoctor of Medicine. Ave achiongorora nekurapa mabundu eropa (lymphoma, multiple myeloma, nezvimwewo) kwemakore anopfuura gumi, uye ane ruzivo rwakakura mukurapa uye akabudirira zvikuru mukuongorora nekurapa marudzi akasiyana-siyana elymphomas nemyelomas, uye ane hunyanzvi mukurapa zvakanangana neimmunotherapy, chemotherapy, CAR-T cell therapy, hematopoietic stem cell transplantation, uye achitungamira kukura kwe multidisciplinary diagnosis and treatment (MDT). Tsvakurudzo yake huru ndeye immunotherapy yakanangana nekutsvaga lymphoma uye drug resistance mechanism, uye akatungamira akawanda eNational Natural Science Foundation of China. Akaburitsa mapepa ehunyanzvi anopfuura makumi mana, kusanganisira mapepa anopfuura makumi matatu ane index yeSCI, ayo akaburitswa muLancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer Therapy Reviews, nemamwe majenari nemajenari. Akaburitsa muLancet Haematology, Journal of Hematology & Oncology, Leukemia, Clinical Cancer Research, Cancer Treatment Reviews, Cancer, British Journal of Cancer, Annals of Hematology, uye Leukemia & Lymphoma. Ndiye mupepeti weStandard Leukemia Diagnosis and Treatment, Standard Multiple Myeloma Diagnosis and Treatment, uye Medical Oncology. Akapihwa mubairo we "Respect for Life-2017 Glory to Healers-Youth Innovation Award", mubairo we "Tongren Elite" muna 2020, mubairo we "Tongren Hospital Outstanding Young Talent" muna 2020, uye mubairo wekutanga we "Tongren Hospital Outstanding Young Talent" muna 2020. Tongren Hospital Outstanding Young Talent" muna 2020, '35 Young Oncologists Under 35 with the Most Potential in China'. Academic Affiliations: Young Member of the Hematology Branch of the Chinese Medical Association; Standing Member of Lymphoma Immunotherapy Committee of the Beijing Cancer Prevention and Control Society; Standing Member of Myeloma Committee of the China Medical Education Association; Expert of the National Natural Science Foundation of China. Iye mupepeti weAging Pathobiology and Therapeutics, nhengo yebhodhi revatori venhau reChinese Journal of Cancer Prevention and Control, nhengo yebhodhi revatori venhau reConcord Medical Journal, uye muongorori weJournal of Hematology & Oncology and Cancer Biology & Medicine.

Wang Liang